While many guidelines have now acknowledged that apoB is the most accurate lipid marker of ASCVD risk and response to therapy [17,18,19], and the European guideline has endorsed these assays as well-standardized and accurate and acknowledged that they are superior to the measurement or calculation of LDL-C and non-HDL-C [18], there are still those that question the reliability of apoB measurements [19]. The gene discussed is APOB; the disease is atherosclerosis.